Atlanta Electricals’ ₹687.34 crore mainboard IPO closes today with strong demand led by NIIs and solid traction from retail and QIBs; GMP has stayed supportive into the final session. Here are the time‑stamped Day‑3 subscription snapshots, today’s GMP context, and the exact next steps for allotment and listing.
Day‑3 subscription snapshot
- Midday update: Overall ~9.69x; NII ~23.56x; Retail ~6.05x; QIB ~5.83x as of around 12:55 PM IST per exchange‑aligned reports. End‑of‑day totals will update after 5 PM.
- Earlier Day‑3 tick: Around 10:40 AM, overall ~4.5x with QIB ~1.5x, NII ~9.8x, Retail ~4.0x, showing rapid build through the session.
- Context: Day‑2 ended ~3.07x overall; book momentum accelerated sharply on the final morning.
GMP today
- Live quotes: Unofficial GMP hovered near ₹124–₹136 on Sep 24 late morning to midday, implying an estimated listing zone around ₹878–₹890 versus the ₹754 cap. Treat GMP strictly as sentiment, not a forecast.
Allotment and listing timeline
- Basis of allotment: Thu, Sep 25, 2025.
- Refunds/UPI release and demat credit: Fri, Sep 26, 2025.
- Listing: Mon, Sep 29, 2025 on BSE & NSE at 10:00 AM.
How to check allotment
- Registrar (MUFG Intime): Use the Public Issues page to select “Atlanta Electricals Ltd.” and search via PAN/Application/DP ID when the basis is published.
- BSE “Status of Issue Application” and NSE “Equity IPO bid details” can be used to cross‑check application status.
What to watch into listing
- Category mix: Sustained NII leadership plus improving QIB build usually supports debut confidence, but watch the final exchange print.
- Market tone: Broader risk sentiment often dominates SME/mainboard debuts regardless of late GMP strength.
- Free float and OFS: Mixed fresh + OFS can influence supply dynamics; monitor allocation and anchor flows in the RHP.
Bottom line: Atlanta Electricals closes Day‑3 with strong oversubscription momentum and a supportive GMP; check the registrar for the basis on Sep 25, track refunds/demat on Sep 26, and approach the Sep 29 listing with a clear plan aligned to risk tolerance rather than GMP alone.